Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IGC Pharma (NYSE American: IGC)/b) announced that Ascendiant Capital Markets raised its price target to in a new equity research report.
The report, focused on clinical progress and potential 2026 catalysts, centers on IGC-AD1, now in the Phase 2 CALMA trial for agitation in Alzheimer’s disease.
Details
News Market Reaction – IGC
On Jun 9, the day this news came out, IGC closed 4.68% below the previous close. That session’s volume was 1.9x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Jun 9 session.
Key Figures
- Price target
- $5.50 per share
- Ascendiant Capital Markets updated equity research report
- Trial phase
- Phase 2
- CALMA trial of IGC-AD1 for agitation in Alzheimer’s disease
- Catalyst year
- 2026
- Ascendiant cites additional 2026 clinical data and progress as catalysts
Historical Context
-
Added Mount Sinai site with ~80% of CALMA participants completing the study.
-
Reported Q1 2026 results and 80% enrollment of 146-patient CALMA target.
-
Announced Tau-PET biomarker research presentation at 2026 Global Tau Conference.
-
Highlighted caregiver podcast participation and CALMA enrollment at ~80% toward completion.
-
Added Kerwin Medical Center site with ~80% CALMA enrollment and neurology expertise.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
equity research report financial
price target financial
clinical-stage medical
phase 2 medical
clinical trial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued an updated equity research report on the Company, raising its price target to

According to Ascendiant, the updated report highlights the Company's clinical progress and states that additional clinical data and progress in 2026 could serve as strong catalysts for IGC Pharma's stock.
IGC Pharma's lead program, IGC-AD1, is currently being evaluated in the Phase 2 CALMA clinical trial for agitation associated with Alzheimer's disease. The Company continues to advance CALMA toward its next operational and clinical milestones.
The Ascendiant report, entitled "Reports Q1 2026. We believe more positive clinical data and progress in 2026 to be strong catalysts for stock. Raising P/T to
All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC does not endorse, adopt, or guarantee the accuracy, completeness, conclusions, projections, or recommendations contained in any analyst report and undertakes no obligation to update or correct such information.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including risks related to the Company's ability to complete enrollment in its Phase 2 CALMA trial within anticipated timeframes, demonstrate safety and efficacy, the timing of data readouts, regulatory approvals, and other factors discussed in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-KT. The Company undertakes no obligation to update these statements.
Contact Information:
Andres Sanchez
Investor Relations
info@igcpharma.com
+1 301-983-0998 / +1 (202) 569-2566
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.